ERBB2 and colon carcinoma: Moreover, as reported by the same research group, CA antitumor mechanism is not limited to HER2/HER3 pathway inhibition; the results of in vitro and in vivo colon carcinoma xenograft models revealed that, by down-regulating HER2/HER3, CA also inhibited its two classic down-stream pathways PI3K/Akt and Ras/Raf/MAPK, thus decreasing the Drp1 phosphorylation, which resulted in mitochondrial dynamics changes responsible for the CA anticancer effects (Table 2) [118].